Related Experiment Video

Updated: Jul 5, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.8K

Atorvastatin Effect on COVID-19 Outcomes: A Propensity Score Matched Study on Hospitalized Patients

Mohamad Amin Pourhoseingholi1, Omid Yazdani1, Mehdi Azizmohammad Looha2

  • 1Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Current Medicinal Chemistry
|January 22, 2024
PubMed

Insights

Atorvastatin use in COVID-19 patients was associated with reduced in-hospital mortality but did not affect intensive care unit (ICU) admission. Further research is needed to confirm these findings on COVID-19 outcomes.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Investigated the impact of atorvastatin on COVID-19 patient outcomes, including survival, ICU admission, and hospital length of stay.
  • Retrospective analysis of COVID-19 inpatients admitted between March 2020 and March 2021.

Purpose of the Study:

  • To determine the association between atorvastatin use and prognosis in COVID-19 patients.
  • To evaluate the drug's effect on mortality, ICU admission, and length of hospital stay.

Main Methods:

  • Retrospective cohort study involving 4322 COVID-19 patients.
  • Propensity score matching (PSM) used for 1:1 patient-control balancing.
  • Analysis of unadjusted and adjusted effects of atorvastatin on COVID-19 prognosis.

Main Results:

  • Atorvastatin use was linked to decreased COVID-19 mortality (HR: 0.80; 95% CI: 0.68-0.95).
  • No significant association found between atorvastatin and ICU admission (HR: 1.21; 95% CI: 0.99-1.47).
  • Atorvastatin group had a significantly longer hospital stay (p = 0.003); combination therapy with enoxaparin improved survival.

Conclusions:

  • Atorvastatin may reduce in-hospital mortality for COVID-19 patients.
  • Considered a potentially beneficial add-on therapy for COVID-19.
  • Randomized trials are recommended to validate these observational findings.
Abstract

Keywords:
AtorvastatinCOVID-19SARS-CoV-2enoxaparinhydroxymethylglutaryl-CoA reductase inhibitorsmortalitypropensity score.

More Related Videos

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient07:16

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

Published on: November 30, 2022

3.3K
Author Spotlight: A Non-Intubated Video-Assisted Thoracoscopic Surgery with Multimodal Analgesia and Sevoflurane Inhalation Anesthesia05:39

Author Spotlight: A Non-Intubated Video-Assisted Thoracoscopic Surgery with Multimodal Analgesia and Sevoflurane Inhalation Anesthesia

Published on: May 26, 2023

1.5K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
664
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
518
Time Course of Drug Effect01:14

Time Course of Drug Effect

The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.1K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
183
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
166